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Abstract
Background: Although it has been claimed that insomnia causes an increased risk for depression,
adequate controlled trials testing this hypothesis have not been available. This study contrasted the
incidence of depression among subjects receiving hypnotics in randomized controlled trials versus
those receiving placebo.
Methods: The incidence of depression among patients randomized to hypnotic drugs or placebo
was compiled from prescribing information approved by the United States Food and Drug
Administration (FDA) and from FDA New Drug Application documents. Available data for
zolpidem, zaleplon, eszopiclone, and ramelteon were accessed.
Results: Data for 5535 patients randomized to a hypnotic and for 2318 randomized to placebo
were compiled. The incidence of depression was 2.0% among participants randomized to hypnotics
as compared to 0.9% among those randomized in parallel to placebo (p < 0.002).
Conclusion: Modern hypnotics were associated with an increased incidence of depression in data
released by the FDA. This suggests that when there is a risk of depression, hypnotics may be
contra-indicated. Preventive treatments such as antidepressant drugs, cognitive-behavioral therapy,
or bright light might be preferred. Limitations in the FDA data prevented a formal meta-analysis,
and there was a lack of information about drop-out rates and definitions of depression. Trials
specifically designed to detect incident depression when treating insomnia with hypnotic drugs and
better summarization of adverse events in trials submitted to the FDA are both necessary.
Background
There has been interest in the observation that insomnia
predicts the incidence of major depressive disorders [1,2].
From the idea that the presence of insomnia predicts an
increased risk for depression, some have theorized that
insomnia is a cause of depression, implying that insomnia
treatment might prevent depression.
The fact that insomnia predicts depression may simply be
a tautological result of our definition of depression.
According to DSM-IV [3], there are 9 groups of signs and
symptoms which indicate a major depressive disorder.
One of these is insomnia or hypersomnia. If 5 of these
signs and symptoms are present, a diagnosis of major
depressive disorder should usually be made. Since major
depressive disorders often develop gradually as the
number of symptoms increases, several of the 9 groups of
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symptoms are likely to precede the threshold when at least
5 are present. All of the 9 groups of signs and symptoms
of major depression may be premonitory, and all predict
the future onset of the full syndrome. Of the signs and
symptoms of depression, insomnia is not the symptom
with the highest risk factor or predictivity [4-6]. This indi-
cates that insomnia could be a premonitory sign of a risk
of depression but not a cause of major depression, any
more than are the other signs and symptoms which com-
bined, compose the definition of depression. Indeed, an
association of insomnia with future depression may not
prove that insomnia causes depression any more than epi-
gastric pain causes peptic ulcer.
A longitudinal follow-up of insomnia, depression, and
anxiety over time recently observed that insomnia did not
predict future depression a decade later, independent of
prior depression and anxiety, but use of hypnotics did [7].
This raises the interesting possibility that it might not be
insomnia itself, but rather the associated usage of hypno-
tics, which increases the risk of future depression.
To determine whether insomnia itself causes depression,
which might be prevented by use of hypnotics, or whether
hypnotics might rather cause depression, randomized tri-
als would be essential to demonstrate causality.
It happens that to examine long-term effects of modern
hypnotics, pharmaceutical manufacturers have recently
completed randomized trials of unprecedented size and
duration. For the 4 most recently-approved drugs, the tri-
als submitted by the industry in New Drug Applications
(NDA) to the United States Food and Drug Administra-
tion (FDA) are now summarized in data which the FDA
has provided on-line [8]. From the listings of adverse
events in controlled trials, it is now possible to explore
whether the most popular intervention to eliminate
insomnia, the prescription of hypnotic drugs, reduces the
incidence of depression.
Methods
The on-line FDA NDA files for zolpidem, zaleplon, eszo-
piclone, and ramelteon consist of hundreds of pages of
reports, data, interpretations, and correspondence con-
cerning each drug [8]. The text of approved official "Pre-
scribing Information" for each drug was also included.
The files were searched for as much controlled trial infor-
mation as was available. For specific sources of the data,
see Additional file 1. The quality of the data did not make
formal meta-analysis possible. Comparable data for other
hypnotics approved earlier were not available [8].
From this information for each drug, the author extracted
all summaries of parallel randomizing placebo-controlled
trials (or combinations of trials) where the number of
subjects studied in each group and the number suffering
the adverse effect of depression were reported. Most of the
"depression" adverse events tabulated may have been
incident major depressions, but NDA data did not make
clear if that was so. For most of these studies of healthy
subjects and insomnia patients, participants with major
depression at baseline were probably excluded, though
details of exclusion criteria for each trial were often not
available. The author then summed for the groups given
each hypnotic and the comparable groups randomized to
placebo, the total number of participants and the number
of reports of incident depression (Table 1). In general,
information on the definition of depression as an adverse
effect, the type and severity of depression, its method of
ascertainment, and the expertise of the dozens or hun-
dreds of investigators performing these trials was not
available. Dropout rates and the duration of hypnotic
treatment before depression was recognized were not gen-
erally available.
Because the author has not received responses to some
other queries to hypnotics manufacturers, no attempt was
made to obtain additional data on these trials from the
manufacturers. It was presumed that the data presented by
the FDA are unbiased, though in many respects incom-
plete.
Results
The sum of these compilations for the 4 hypnotics is pro-
vided in Table 1. Because several doses of the investiga-
tional hypnotics were compared to a placebo in some
randomizing trials, there were more participants receiving
hypnotics than parallel placebo. For each of the 4 hypno-
tics, the rate of incident depression was higher among par-
ticipants randomized to hypnotic drugs (2.0%) than
among contrast controls randomized to placebo (0.9%).
Assignment to hypnotics was significantly associated with
incident depression (Chi-Square = 10.04, p < 0.002). For
incident depression, the risk ratio comparing hypnotics
with placebo was 2.1 (95% Confidence Interval 1.3–3.3).
Discussion
These data indicate that in randomized trials, depression
was reported among participants receiving modern hyp-
notics significantly more often than among participants
randomized to receive placebo. A possible interpretation
would be that hypnotics are more likely to cause depres-
sion than to prevent it.
This is a post-hoc analysis of trials which were not
designed primarily to examine depression. The compila-
tion had many limitations which have caused some
observers to doubt that causality has been demonstrated.
Information limitations included trial details, the length
of exposure of many participants (correcting for drop-BMC Psychiatry 2007, 7:42 http://www.biomedcentral.com/1471-244X/7/42
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outs), and inadequate specification of the nature and
severity of incident depressions. The quality of ascertain-
ment of depression occurring as an adverse event was
quite uncertain. It is not evident that a major depressive
disorder was always diagnosed by an expert when depres-
sion was listed as an adverse event. There are potential sta-
tistical pitfalls in compiling results of numerous trials of
different design and duration using 4 different hypnotics.
Because the FDA online files are a limited source, other
methods of ascertainment might have uncovered more tri-
als of these drugs, especially post-marketing trials. The
data utilized did not lend themselves to the techniques of
formal meta-analysis. Many limitations of this compila-
tion could not be overcome unless new trials with thou-
sands of participants are done, so some uncertainty as to
the present conclusions is unavoidable.
If drop-out rates were far higher in placebo than hypnotic
groups, a greater incidence of depression in hypnotic
groups might be attributable to longer exposure, but the
study of Krystal et al. did not report an important differ-
ence in overall drop-out rates [9]. Notably, Krystal et al.
reported a dropout rate of 2% due to depression in the
eszopiclone group (presumably 12 participants) and 0%
in the placebo group (Chi Square = 3.9, P < 0.05, my com-
putation). Krystal et al. did not describe all 30 incident
depressions listed in the FDA data for the same study (see
Additional file 1 and [9].) One might suppose that drop-
outs had depression of sufficient severity to meet criteria
for major depressive disorders, but depressions which did
not cause dropout may have been milder. Dropout rates
did not accompany incident depression rates in FDA data
for the other studies.
Supporting the hypothesis that hypnotics cause depres-
sion is the statistical robustness of the results and the con-
sistency of the subsamples (see Additional file 1), which
all revealed more incident depression in hypnotic than
placebo groups. Though the trial data analysed were
unclear about the severity of the depressions which were
associated with hypnotic use, a severe risk has been sug-
gested by epidemiologic data, which found that the sui-
cide rate was markedly elevated among hypnotic users at
a time before the drugs listed in Table 1 came on the mar-
ket [10,11]. It is also known that overall mortality has
been elevated among hypnotics users, though it is
unlikely that this increase in overall mortality would be
largely attributable to depression [12]. Since the epidemi-
ologic association data for the earlier drugs may be less
indicative of causality than randomized trial results, it is
unfortunate that the FDA web site did not report clinical
trial data for the benzodiazepines popular in the 1980's,
such as temazepam, flurazepam, and triazolam.
Many patients believe that better sleep can relieve depres-
sion, but sleep deprivation is known to be a powerful anti-
depressant treatment [13]. It is currently unknown if small
increments in sleep, such as those produced by hypnotics,
would tend to cause or to relieve depression. A recent
meta-analysis raised a question whether newer nonbenzo-
diazepine hypnotics might increase total sleep time only a
negligible amount [14]. Currently under investigation is
whether cognitive-behavioral therapy (CBT) for insom-
nia, which often includes sleep restriction, will prove to be
antidepressant [15-18]. A form of CBT which did not
emphasize sleep restriction has been shown to improve
sleep quality and general mental health [19,20].
One recent manufacturer-sponsored study might appear
somewhat in conflict with these results [21]. Fava and col-
leagues reported that symptoms of major depression were
reduced when eszopiclone was added to fluoxetine treat-
ment. Considering reduction in Hamilton Depression
Scores (with insomnia items removed) after 4 weeks, the
effect of eszopiclone was not significant, but after 8 weeks,
the improvement in depression scores was 13% greater
with eszopiclone than with fluoxetine alone (p = 0.04).
These results referred not to preventing the risk of major
depression but to treating depression with fluoxetine once
depression with related insomnia had appeared. Fluoxet-
ine would be a poor choice of antidepressant among
patients selected for insomnia symptoms, since fluoxetine
often reduces sleep efficiency when an alternative such as
trazodone would increase sleep efficiency [22]. This might
be an example of a post-marketing trial designed to make
the manufacturer's product appear favourable [23]. In any
case, the finding of Fava et al. involved fewer participants
and was less significant than the data in Table 1.
Another industry-supported study compared zolpidem 10
mg. vs. placebo in patients receiving one of 3 SSRI antide-
Table 1: Depression incidence for four hypnotics and parallel 
placebos
Drug N 
subje
cts
Depressio
n 
incidence
Zolpidem 353 6
Zolpidem placebo 377 2
Eszopiclone 802 32
Eszopiclone placebo 294 3
Zaleplon 786 24
Zaleplon placebo 277 6
Ramelteon 3594 48
Ramelteon placebo 1370 11
Total of 4 hypnotics 5535
*
110 
(2.0%)*
Total of 4 placebo groups 2318
*
22 (0.9%)*
*Chi Square = 10.04, p < 0.002, risk ratio = 2.1BMC Psychiatry 2007, 7:42 http://www.biomedcentral.com/1471-244X/7/42
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pressants (groups of 95 and 97 respectively) [24]. There
were no significant differences between zolpidem and pla-
cebo in the non-sleep items of the Hamilton Depression
Rating Scale. Similar to results of Krystal et al., there were
two dropouts due to depression and one due to mania in
the zolpidem group but none in the placebo group [24].
Another manufacturer-supported trial found that meno-
pausal women randomized to eszopiclone had, on aver-
age, a significant improvement in mood compared with
those who received placebo; however, the full ANCOVA
statistics were not reported nor were the adjusted mean
improvements [25]. One can infer that the difference
between eszopiclone and placebo was only about 1 point
on a small self-report scale which might confound sleep
and mood. Any improvement might have occurred only
in sleep. The mood result was reported as P < .05, which
would not be significant after correction for multiple test-
ing. This study reported no incident major depressions in
either the hypnotic or placebo group.
In summary, the published literature partly supports and
partly seems to contradict the compiled FDA data suggest-
ing that hypnotics trigger depression. It is possible that
hypnotics produce little effect on the median mood score
but an increased the incidence of problematic exacerba-
tions of depression.
Conclusion
The quality of data which can be gleaned from published
studies and unpublished NDA data available from FDA is
not fully satisfactory, but manufacturer-sponsored trials
show that hypnotics may be contra-indicated when
insomnia signals a risk of depression developing. When
premonitory insomnia occurs, preventive treatments such
as antidepressant drugs, depression-oriented cognitive-
behavioral therapy, and bright light treatment may be pre-
ferred.
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